We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
The Cauldron is a technology-led entertainment studio that aims to deliver immersive experiences to its guests by combining technology with food and drink. Upon entering the company's venues, guests are given a magic wand, which acts as a control device for their visit. It helps them pour pints, activate lights and locks, explore science experiments, and stir cocktails. The device is also programmed to act as an open bar tab to track user spending. The Cauldron has served 1 million potions till date, welcomed 260,000+ guests and built a mailing list of over 72,000 subscribers. The company has featured in publications like Thrillist, NBC, Forbes, and Edinburgh News. The Cauldron will use 40% of the investment to open a central-London Cauldron flagship and provide additions to its Wands & Wizard Exploratorium, a new five-floor venue on Greek Street in the very heart of London’s Soho, 40% to grow its retail technology, and 20% to pay staff salaries.
days to go: Expired investment: £364,143
Tribal Sports Nutrition (TSN) uses the revitalising properties of the Baobab fruit to create energy smoothies. TSN claims that its smoothies are less concentrated than other sports nutrition brands, are 100% organic, and easy on the stomach. The company also incorporates vitamin C, antioxidants, fibre, and electrolytes into the smoothies to make it the on-the-go snack for active lifestyle consumers. TSN asserts that its baobab ingredient is wild-harvested by cooperatives in Africa, bringing income to people and preserving the local ecology. The company received a certification from the Organic Food Federation (OFF) and aims to achieve B Corp status. TSN's products have been listed in Sainsbury's and on Amazon. It will use the investment to double its existing product offering in 2021 and launch hydration, plant protein recovery products, and Baobab energy snacks.

Pitch Rated

86%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £421,647
Hawkens Gingerbread is a bakery that makes gingerbread products that are diverse, rich in heritage, delicious, and high in quality. It has spent three years in a start-up phase and now targets a three-year phase of stage one growth. Currently, its facility can bake up to 80,000 units of gingerbread each month. Since 2017, it is consistently producing a 65% average gross profit margin across its B2C and B2B markets. This company has been growing for three years, and in the financial year 2019, its revenue grew 108% to £43k (£25k profit). Its online sales are displaying a strong flow in the upwards direction. Fund raised will enable it to get in front of a much wider audience and bring the necessary skills into the business.
days to go: Expired investment: £67,110
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go: Expired investment: £2,160,000
Doctaly is  the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go: Expired investment: £807,580
The Wine List (WL) gives confidence to wine lovers through a home wine course. The company argues that 20% of the UK's wine drinkers fall into a cohort that is actively engaged, spend at the higher end of the market, and frequently drink from a variety of sources. But less than 20,000 people don't have the requisite knowledge about different wine styles and tastes. WL aims to change this scenario by offering a home wine course to customers where alongside their wine lessons, they also get two bottles of wine to practice their skills on. The company has shipped 20,000+ bottles of wine and witnessed revenues of £298,000 in April-October 2020. WL is also building a digital content platform that will offer best in class video lessons, with learning quizzes to reinforce knowledge. The company has featured in Metro, Evening Standard, and Courier. It will use the investment to increase content production, wine delivery and scale into 2021.

Pitch Rated

38%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £505,494
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph